RNA - Why Is RNA Therapeutics-Focused Avidity Biosciences Stock Trading Higher Today? | Benzinga
Avidity Biosciences Inc (NASDAQ: RNA) announced a global licensing and research collaboration with Bristol Myers Squibb & Co (NYSE: BMY) focused on discovering, developing, and commercializing multiple cardiovascular targets with potential cumulative payments of up to $2.3 billion.
Antibody Oligonucleotide Conjugates (AOCs) combine monoclonal antibodies' specificity with the precision of oligonucleotide therapies to target the root cause of diseases previously untreatable with RNA therapeutics.
This strategic collaboration broadens the reach of AOCs by expanding the ...